Baseline demographic and clinical characteristics of the Chinese subgroup and overall study population in PATENT-1
| Chinese subgroup | Overall study population | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | Placebo (n=24) | Riociguat 2.5 mg-maximum group (n=43) | Riociguat 1.5 mg-maximum group (n=10) | Total (n=77) | Placebo (n=126) | Riociguat 2.5 mg-maximum group (n=254) | Riociguat 1.5 mg-maximum group (n=63) | Total (n=443) |
| Female, n (%) | 18 (75) | 34 (79) | 9 (90) | 61 (79) | 98 (78) | 203 (80) | 49 (78) | 350 (79) |
| Age, mean±SD (years) | 41±16 | 38±13 | 33±14 | 38±14 | 51±17 | 51±17 | 49±16 | 51±17 |
| Aetiology of PAH, n (%) | ||||||||
| Idiopathic | 17 (71) | 29 (67) | 7 (70) | 53 (69) | 84 (67) | 149 (59) | 39 (62) | 272 (61) |
| Familial | 1 (4) | 4 (9) | 0 | 5 (7) | 1 (1) | 7 (3) | 1 (2) | 9 (2) |
| Connective tissue disease | 2 (8) | 6 (14) | 0 | 8 (10) | 25 (20) | 71 (28) | 15 (24) | 111 (25) |
| Congenital heart disease | 3 (13) | 3 (7) | 3 (30) | 9 (12) | 12 (10) | 15 (6) | 8 (13) | 35 (8) |
| Portopulmonary hypertension | 0 | 1 (2) | 0 | 1 (1) | 2 (2) | 11 (4) | 0 | 13 (3) |
| Anorexigen or amphetamine use | 1 (4) | 0 | 0 | 1 (1) | 2 (2) | 1 (<1) | 0 | 3 (1) |
| WHO FC I/II/III/IV, % | 8/54/38/0 | 2/67/30/0 | 0/50/50/0 | 4/61/35/0 | 3/48/46/2* | 2/43/55/<1 | 8/30/62/0 | 3/42/54/1* |
| In receipt of additional PAH treatment at baseline, n (%) | ||||||||
| No | 22 (92) | 38 (88) | 8 (80) | 68 (88) | 66 (52) | 123 (48) | 32 (51) | 221 (50) |
| Yes | 2 (8) | 5 (12) | 2 (20) | 9 (12) | 60 (48) | 131 (52) | 31 (49) | 222 (50) |
| Endothelin receptor antagonist | 1 (4) | 1 (2) | 2 (20) | 4 (5) | 54 (43) | 113 (45) | 27 (43) | 194 (44) |
| Prostanoid | 1 (4) | 4 (9) | 0 | 5 (7) | 7 (6) | 20 (8) | 4 (6) | 31 (7) |
| 6MWD, mean±SD (m) | 387±50 | 382±51 | 369±51 | 382±50 | 368±75 | 361±68 | 363±67 | 363±69 |
*Data missing for one patient.
6MWD, 6 min walking distance; PAH, pulmonary arterial hypertension; WHO FC, WHO functional class (ranges from I to IV, with higher numbers indicating greater functional limitations).